Literature DB >> 8882618

Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.

G Rammes1, D Swandulla, G L Collingridge, S Hartmann, C G Parsons.   

Abstract

1. The 2,3-benzodiazepines GYKI 52466, GYKI 53405 and GYKI 53655 antagonized AMPA-induced currents in cultured superior colliculus neurones in a non use-dependent manner (steady state IC50s: GYKI 52466 9.8 +/- 0.6 microM; GYKI 53405 3.1 +/- 0.6 microM; GYKI 53655 0.8 +/- 0.1 microM). 2. Higher concentrations of all three antagonists slowed the onset kinetics and quickened the offset kinetics of AMPA-induced currents indicative of an allosteric interaction with the AMPA recognition site. 3. Cyclothiazide (3-300 microM) dramatically slowed desensitization of AMPA-induced currents and potentiated steady state currents (EC50 10.0 +/- 2.5 microM) to a much greater degree than peak currents. Both tau on and tau off were also increased by cyclothiazide in a concentration-dependent manner (EC50: tau on 42.1 +/- 4.5 microM; tau off 31.6 +/- 6.6 microM). 4. Cyclothiazide (10-100 microM) shifted the concentration-response curves of the 2,3-benzodiazepines to the right. For example, with 10 microM cyclothiazide the IC50s of GYKI 52466 and GYKI 53405 on steady-state AMPA-induced currents were 57.9 +/- 9.5 and 41.6 +/- 1.5 microM, respectively. 5. GYKI 53405 and GYKI 52466 concentration-dependently reversed the effects of cyclothiazide (100 microM) on offset kinetics (GYKI 53405 IC50 16.6 +/- 4.2 microM). However, the 2,3-benzodiazepines were unable to reintroduce desensitization in the presence of cyclothiazide and even concentration-dependently slowed the onset kinetics of AMPA responses further (GYKI 53405 EC50 8.0 +/- 2.8 microM). 6. GYKI 52466 decreased the peak amplitude of hippocampal area CA1 AMPA receptor-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics. Cyclothiazide prolonged the decay time constant of AMPA receptor-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude. 7. Cyclothiazide (330 microM) shifted the concentration-response curve for the effects of GYKI 52466 on AMPA receptor-mediated e.p.s.c. peak amplitude to the right (GYKI 52466 IC50 26.9 +/- 9.4 microM). Likewise, GYKI 52466 (30-100 microM)) shifted the concentration-response curve for the effects of cyclothiazide on AMPA receptor-mediated e.p.s.c. decay time constants to the right. 8. In conclusion, cyclothiazide and the 2,3-benzodiazepines seem to bind to different sites on AMPA receptors but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site. The interactions of GYKI 52466 and cyclothiazide on AMPA receptor-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882618      PMCID: PMC1909809          DOI: 10.1111/j.1476-5381.1996.tb16718.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  69 in total

1.  GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.

Authors:  S D Donevan; M A Rogawski
Journal:  Neuron       Date:  1993-01       Impact factor: 17.173

2.  The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy.

Authors:  S E Smith; N Dürmüller; B S Meldrum
Journal:  Eur J Pharmacol       Date:  1991-08-29       Impact factor: 4.432

3.  A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task.

Authors:  R Granger; U Staubli; M Davis; Y Perez; L Nilsson; G A Rogers; G Lynch
Journal:  Synapse       Date:  1993-12       Impact factor: 2.562

4.  Development and properties of synaptic mechanisms in a network of rat hypothalamic neurons grown in culture.

Authors:  D Swandulla; U Misgeld
Journal:  J Neurophysiol       Date:  1990-09       Impact factor: 2.714

5.  Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines.

Authors:  T J Wilding; J E Huettner
Journal:  Mol Pharmacol       Date:  1995-03       Impact factor: 4.436

6.  An analysis of synaptic transmission to motoneurones in the cat spinal cord using a new selective receptor blocker.

Authors:  I Engberg; I Tarnawa; J Durand; M Ouardouz
Journal:  Acta Physiol Scand       Date:  1993-06

7.  Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors.

Authors:  U Staubli; J Ambros-Ingerson; G Lynch
Journal:  Hippocampus       Date:  1992-01       Impact factor: 3.899

8.  Altered desensitization produces enhancement of EPSPs in neocortical neurons.

Authors:  M R Pelletier; J J Hablitz
Journal:  J Neurophysiol       Date:  1994-08       Impact factor: 2.714

9.  Inhibition of hippocampal field potentials by GYKI 52466 in vitro and in vivo.

Authors:  I Tarnawa; P Molnár; L Gaál; F Andrási
Journal:  Acta Physiol Hung       Date:  1992

10.  AMPA receptors have an equal role in spinal nociceptive and non-nociceptive transmission.

Authors:  M J Cumberbatch; B A Chizh; P M Headley
Journal:  Neuroreport       Date:  1994-04-14       Impact factor: 1.837

View more
  6 in total

1.  Mechanism of inhibition of GluA2 AMPA receptor channel opening by 2,3-benzodiazepine derivatives: functional consequences of replacing a 7,8-methylenedioxy with a 7,8-ethylenedioxy moiety.

Authors:  Mohammad S Qneibi; Nicola Micale; Silvana Grasso; Li Niu
Journal:  Biochemistry       Date:  2012-02-13       Impact factor: 3.162

2.  AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate.

Authors:  K M Partin; M W Fleck; M L Mayer
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

3.  Characteristics of AMPA receptor-mediated responses of cultured cortical and spinal cord neurones and their correlation to the expression of glutamate receptor subunits, GluR1-4.

Authors:  W M Dai; J Egebjerg; J D Lambert
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 4.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

5.  Bidirectional modulation of GABA release by presynaptic glutamate receptor 5 kainate receptors in the basolateral amygdala.

Authors:  Maria F M Braga; Vassiliki Aroniadou-Anderjaska; Jianwu Xie; He Li
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

6.  The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine.

Authors:  Hai Xia Zhang; Krzysztof Hyrc; Liu Lin Thio
Journal:  J Physiol       Date:  2009-05-11       Impact factor: 5.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.